We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Cello Health Plc | CLL | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 161.00 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 161.00 | 161.00 |
| Top Posts |
|---|
Posted at 05/6/2020 14:40 by qs99 US market recovery and economic news today, may help CLL....let's see |
Posted at 20/5/2020 07:39 by davebowler Cenkos-Navigating positively through disruptions Cello’s AGM statement should reassure that FY20 trading to date remains robust, underpinned by “solid” growth in net revenue in Q1/20. While Q2/20 saw certain early disruption, overall progress has been made to maintain revenues alongside effective cost controls, thus a creditable H1/20E result is expected. The 23% fall in the shares since February’s highs, appears to overly discount for the actual reality of this disruption. Despite some disruption in Q2/20, the Cello Health division continues to perform: Q1/20: Cello Health delivered “strong” overall net revenue and profit growth over Q1/20, benefitting from ISS’s acquisition in August 2019. On a LFL basis, excluding ISS, organic growth has been described as “good”, continuing recent momentum. Q2/20: Commentary on trading post the COVID-19 outbreak suggests of continued progress, with new win rates being maintained, leading to a continuation of the typical six month visibility to bookings going into H2/20. This comes despite some disruption in activities requiring physical proximity (healthcare conventions, expert focus groups etc), which are being digitally delivered or have been put on hold. Some COVID-19 benefits: New projects have arisen as result of the pandemic, with Cello Connect, the digital and creative marketing capability transferred from Signal, delivering COVID-19 related public health campaigns, while newly acquired ISS is also benefitting from new US regulatory drug approvals and FDA fillings. Signal expected to be more impacted, but it’s far less material this year: Cello Signal generated only 16% of net revenue in Q1/20 following Connect’s transfer at the start of the year. Over Q2/20 and beyond, trading is unsurprisingly expected to be challenged by COVID-19, given certain clients are engaged in troubled sectors (eg travel, leisure), thus some delays and cancellations are expected. As such, cost control measures have, and continue to be undertaken, where necessary. Balance sheet remains strong: Today’s update confirms Cello maintains a “solid” net cash position. This comes despite a seasonal working capital outflow in Q1/20 and is inclusive of a £0.7m payment for the final earn-out payment on Defined Health and FY19A’s £1.1m final dividend. The implies positive cash generation to date this year. Valuation: Prior to the COVID-19 outbreak, Cello traded at a forward P/E of 16.0x in late February, a multiple we feel is merited. If Cello were to deliver a FY20E result largely consistent with FY19A, a price today of 151p p/s (+32% upside) would be fair. |
Posted at 07/4/2020 11:37 by coopstock Cutting the dividend just one week after announcing the award of all those new share options for senior directors. All in this together - I don't think so. Pretty poor. |
Posted at 07/4/2020 07:41 by poikka I suppose that the idea of cutting the divi so soon after announcing it, is designed to demonstrate solidarity with those taking a pay cut.The saving, even if it is (hopefully) temporary, would be some £2m. 1. It sounds like a noble gesture - 'we're all in this together'. 2. As the situation hasn't really changed, nor has the outlook, since the results, it looks odd. They could have just not increased the divi at the results. 3. Companies cutting divis without very good reason are removing cash from the economy when it's really going to be needed, and there are many people who rely on divis for their sole, or nearly sole, income. A wrong decision, therefore, in my book. |
Posted at 06/4/2020 17:08 by poikka (Alliance News) - Access Intelligence PLC on Monday reported a widened loss for financial 2019 on increased expenses but assured that the first quarter of financial 2020 has been encouraging.The stock was trading 3.0% higher at 51.00 pence each on Monday afternoon in London. For the year to the end of November, the PR, communications and marketing software firm recorded revenue of GBP13.4 million, a 51% rise from GBP8.9 million reported the year prior with recurring revenue accounting for 97% of revenue realised. However, pretax loss widened to GBP2.9 million from GBP1.7 million. Gross margin was 75% from 70% the year prior. Recurring administrative expenses increased to GBP9.2 million from GBP6.2 million and the company recorded non-recurring administrative expenses of GBP1.8 million. In October, GBP3.3 million was raised through the placing of 6.3 million shares at 52p each. Access Intelligence did not propose a dividend payout, unchanged from the year prior. Looking ahead, the company said it has seen increased demand for Vuelio stakeholder monitoring, media management and Pulsar's online audience analysis amid the Covid-19 outbreak. It added that it has implemented measures to reduce financial risk and has responded fast and proactively to secure business and open new opportunities during the period of disruption. "2019 was another year of strong growth for Access Intelligence. Our commitment to growth was evidenced by the acquisition of Pulsar and further product enhancements to the Vuelio and ResponseSource platforms, said Non-Executive Chair Christopher Satterthwaite. Vuelio provides monitoring, insight, engagement and evaluation tools for social media, while ResponseSource is a media database provider. Access Intelligence bought social media analytics software business Pulsar from Cello Health in October. "Pulsar is a particularly exciting addition because it strengthens our technology, data and research capabilities while opening US and global opportunities. It adds further breadth to the Access Intelligence portfolio and customer base providing resilience as we navigate the immediate uncertainty bought by Covid-19," he added. |
Posted at 18/3/2020 08:18 by poikka Not much at all, so far. In the present climate, a 7.2% divi rise is welcome. |
Posted at 03/3/2020 12:18 by zipstuck As the major drug companies are being squeezed on supply chains you have to wonder how this might affect CLL |
Posted at 18/7/2019 18:20 by qs99 nice uptick today. A guarded upgrade IMO, yet market hasn't really digested it....more to come, maybe increase in divi? DYOR |
Posted at 18/7/2019 09:26 by qs99 if that is an average of the peer group, how long before someone takes "a look" at CLL? or management get bored with the share price and do something about it?! DYOR |
Posted at 21/1/2019 09:20 by zipstuck Reasonable divi with some growth to come |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
